

Our partnership with the uMed research platform

Castle Meadows Surgery is currently working with a research technology partner known as uMed. Their accredited platform enables us to provide you with research opportunities that are highly relevant to your health circumstances.

Without the use of uMed's technology we may not have the time to find and engage patients that meet the requirements of the studies. This would therefore mean many patients would miss out on their chance to participate in ground-breaking research.

For further information on uMed please visit their website at www.umed.io or email patientsupport@umed.io

Practice Privacy Notice Statement

Supporting Research Activity

Castle Meadows Surgery uses Umedeor Ltd (uMed) as a data processor to support research and care support activity. This includes accessing and secure hosting of health record data for the purpose of identifying patients that are eligible for specific research or care support projects. uMed also contacts those patients on behalf of the practice via SMS, letter, email or telephone to provide more information about the study, and to collect additional information to assess your eligibility for a certain study.

Your consent will be required before any practice data is shared externally with researchers. uMed applies the national opt-out to practice data it receives so if you wish your data is not processed for research you can do so by visiting <https://www.nhs.uk/your-nhs-data-matters/>

For further information on uMed please visit their website at www.umed.io or email patientsupport@umed.io

The Von Willebrand Disease Study

Castle Meadows Surgery are taking part in the Von Willebrand Disease study which aims to assess the total and treated bleeding event rate in participants with von Willebrand Disease (VWD) on standard of care prophylaxis or on demand treatment, to identify potential participants and establish a historical comparator for future clinical studies.

This study is recruiting male and female participants between the age of 18 to 65 years of age with a confirmed diagnosis of Type 1 Von Willebrand Disease.

Castle Meadows Surgery is working with our research technology partner uMed to invite patients to this study. If you meet the study criteria, you may receive a text message, email or letter asking whether you would like to take part. Participation is entirely voluntary and you can opt out at any time.

If you have any questions about this study please contact the uMed nurse support team at patientsupport@umed.io.
